Functional membrane changes due to tumor induction in rat pituitary cell cultures.
Membrane functions in tumorous cells are different from those in healthy cells. The aim of the present study was to investigate the changes in pituitary cell membrane functions and hormone secretion after tumor induction in vivo and in vitro. Prolactinomas were induced in vivo in female Wistar rats with estrone acetate. Normal anterior pituitaries and prolactinomas of female Wistar rats were dissociated enzymatically and mechanically, then cultured on collagen-treated plastic dishes. Some normal anterior pituitary cultures were treated with benz(c)acridines as tumorigenic agents in vitro. Intracellular 3',5'-cyclic-adenosine monophosphate (cAMP) levels were determined by a competitive binding technique, membrane fluidity was assayed by fluorescence anisotropy, and ATP-ase activities were estimated via ATP loss. The results indicated decreased membrane fluidity in tumorous cell cultures. However, in vitro benz(c)acridine treatment exerted more pronounced effects than those observed after in vivo estrone treatment. The ATP-ase activities were highly increased in benz(c)acridine-treated cells and in estrogen-induced prolactinoma cells, more strongly so in the former ones. The intracellular cAMP levels were higher than normal in both of them. The results concerning the ACTH, alpha-MSH, PRL and GH levels of normal and tumorous cell cultures were published in our previous study. Our findings show that the tumorous transformation of pituitary cells can cause significant changes in functional membrane parameters and hormone secretion. Decreased membrane fluidity was accompanied by an increased exocytosis (hormone release) and adenylate cyclase activity in tumorous cells.
Endocrine Unit,Albert Szent-Gyorgyi Medical and Pharmaceutical Center, University of Szeged, Hungary.
M
M
Gálfi
W K
WK
Khalil
Z
Z
Valkusz
L
L
Gáspár
A
A
Juhász
J
J
Julesz
J
J
Molnár
D000166:Acridines / Q000633:toxicity; D000818:Animals; D002273:Carcinogens / Q000633:toxicity; D002462:Cell Membrane / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure*; D002471:Cell Transformation, Neoplastic; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism; D004970:Estrone / Q000031:analogs & derivatives* / Q000633:toxicity; D005260:Female; D008560:Membrane Fluidity / Q000187:drug effects; D010903:Pituitary Gland, Anterior / Q000187:drug effects / Q000473:pathology* / Q000648:ultrastructure*; D010911:Pituitary Neoplasms / Q000473:pathology / Q000648:ultrastructure*; D015175:Prolactinoma / Q000473:pathology / Q000648:ultrastructure*; D051381:Rats; D017208:Rats, Wistar; D014407:Tumor Cells, Cultured
D000166:Acridines; D002273:Carcinogens; D004970:Estrone; C014945:acetoxyestrone; C035985:benz(c)acridine; D000242:Cyclic AMP